Team

He became Managing Director of TIS Applications Ltd in 1984 and a main board director of TIS Ltd prior to its acquisition by Misys in 1989. He organised the management buyout of the social housing division of Misys and became Group Chief Executive of Comino Group plc when it floated on AIM in 1997. Comino moved to a full listing in 1999 where he remained until its successful public sale to Civica plc in February 2006. Garth joined ANGLE as a non-executive Director in September 2006.

Andrew has an MA in Engineering Science from the University of Cambridge, and is a qualified Chartered Accountant. After working with the engineering conglomerate, TI plc, he worked for KPMG from 1982 to 1994; from 1985 to 1987 he was based in the US as a manager providing corporate finance and business advice to high technology firms in the area around Route 128, Boston, Massachusetts. During this time, he lead KPMG’s involvement in the IPO of the medical technology company Cardio Data Inc. From 1987 to 1994 he worked for KPMG in the UK with responsibility for establishing KPMG's UK and European High Technology Practices and High Technology Consulting Group.

Andrew founded ANGLE in 1994. Together with ANGLE's senior management team, Andrew has co-founded and led eleven technology companies in partnership with world class research organisations, both in the UK and the US. Andrew has been instrumental in developing and then delivering the business proposition for these companies, building management teams, raising finance and securing revenues.

In 1999, Andrew lead the team that founded the medical diagnostic company, Acolyte Biomedica. Acolyte was the first ever spin-out of dstl Porton Down, which specialised in rapid diagnosis of MRSA the ‘hospital super-bug’. Andrew chaired the company for several years and successfully lead the company through three major rounds of venture capital investment.

Andrew also founded Provexis, the first ever spin-out of Rowett Institute, Europe’s leading nutrition research institute. Andrew chaired the Board of Provexis, a specialist nutraceutical company with a heart-health product, through to its successful flotation in 2005.

Andrew was a founder and is currently chairman of ANGLE’s major medical diagnostic businesses, Novocellus and Parsortix.

Ian has a BSc in Mathematics with Management Applications from Brunel University and is qualified as a chartered accountant. For seven years he worked for KPMG, initially in accountancy (1986 to 1990), then in management consulting (1990 to 1993) within KPMG's High Technology Consulting Group where he specialised in financial modelling, business planning, corporate finance, market development and strategy work. After a career break he joined ANGLE in 1995.

As well as leading the finance function at ANGLE plc, he has been closely involved with the development and delivery of the UK, US and Middle East Consulting and Management businesses and in developing new Ventures both third party and ANGLE’s own. Ian has been heavily involved in the start-up phase and also the ongoing development of ANGLE’s own ventures by working closely with management on business plans, financial and operational management, fund raising and commercial aspects, including for both medical and physical sciences companies. He is currently leading the financial development of ANGLE’s major medical diagnostic businesses, Novocellus and Parsortix and its computer gaming business Geomerics.

He is currently the Chairman of RCM Technology Trust plc and a Director of Foresight 2 VCT plc, Private Equity Investor plc and Medical Research Council Technology Limited. David was Chairman of the British Venture Capital Association in 1996/97 and was awarded a CBE in 2008 for services to the Venture Capital industry.

He was President of the British Society for Haematology in 1998-9 and was Chairman of the Science and Education Committee of the International Society for Haematology until 2009. He was awarded the British Society for Haematology Gold Medal in 2008. He was President of the Royal College of Pathologists from 2005 to 2008.

He chairs the National Blood Transfusion Committee and is pathology lead for NHS London. He is currently chair of the Diagnostic Assessment Programme for the National Institute for Health and Clinical Excellence (NICE), responsible for appraisal of new diagnostics and is a member of the NICE Sifting Group for cancer drugs.

Adrian has been a Member of the Scientific Advisory Panel of the Institute of Cancer Research from 1995 until 2003 and Chair of the London Cancer New Drugs Group since 2002 and also chairs the London Cancer Drugs Fund committee. He was a Member of the National Chemotherapy Advisory Group from 2003 to 2009. He has been a Member of the National Chemotherapy Implementation Group since 2010 and a Member of the Expert Reference Group on Cancer Care in London since 2009 and a current member of the national Cancer Outcomes Advisory Group and the Human Genome Strategy Group.

Ashok’s research has helped to elucidate the connections between chromosome instability and the genesis of epithelial cancers. He has been instrumental in establishing the Cambridge Molecular Therapeutics Programme, an initiative that links chemists, physicists, structural biologists, cancer biologists and clinicians at the University of Cambridge, with the aim to pioneer innovative new approaches for the discovery and early clinical development of next-generation medicines.

Ashok has been a member of the Scientific Advisory Boards of Astex Therapeutics Ltd, Cambridge Antibody Technology (AstraZeneca affiliate), Massachusetts General Hospital Cancer Center and currently chairs the Scientific Advisory Board of Sentinel Oncology Ltd. He has also been a John H Blaffer Lecturer at M D Anderson Cancer Center.

Ashok was elected a Fellow of the Academy of Medical Sciences, London, in 2001, and a Member of the European Molecular Biology Organization (EMBO) European Academy, Heidelberg, in 2004.

Shane's professional roots are in biomedical research. He gained his D.Phil in the Cancer Research Unit at the University of York, and from there joined the Fred Hutchinson Cancer Center in Seattle as a post-doctoral fellow. Returning to England, he spent several years as a senior researcher at the Institute for Animal Health before moving to the private sector. His research experience has encompassed chemical carcinogenesis, molecular and viral oncology, control of retrovirus infection, and agricultural applications of transgenic technology. Shane has combined his technical background with a successful career in the private sector. He has held sales, marketing and business development positions in the laboratory equipment group, Sartorius, and at Anderman, where his responsibility included development of OEM business in the diagnostics and pharmaceuticals sectors for specialised membranes produced by German group, Schleicher and Schuell. Shane’s broad experience in the biotechnology field is a key asset in the development of our portfolio companies positioned in the healthcare sector. His management of Parsortix has generated major success in its technical and commercial development.

Dr. Hvichia is the author of several peer-reviewed publications on microdevices, currently holds two US patents in field of Diagnostic Microstructures and has several more patents pending for the Parsortix technology.